Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2024

Feb 16, 2024

33148_dirs_2024-02-16_577e1e3b-b763-4d3c-9310-49e9046f1877.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-02-14

Reporting Person: Patel Kinnari (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-14 Common Stock M 26189 Acquired 245478 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-14 Restricted Stock Units $ M 3990 Disposed Common Stock (3990) Direct
2024-02-14 Restricted Stock Units $ M 22199 Disposed Common Stock (22199) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 5675 Indirect
Common Stock 101594 Indirect

Footnotes

F1: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.

F2: The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.

F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal annual installments over the following two years.

F5: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal annual installments over the following two years.